explore -WSS

explore

author：entertainment 2025-10-04 04:00:00 - browse：7975

A medical device to treat below-the-knee chronic limb-threatening ischemia, Esprit BTK resorbable scaffold, is shown consisted of pieces of geometric shapes that lined up into a pipe on a blue background — health tech coverage from STAT — Cardiovascular doctors are optimistic about Abbott’s new below-knee stent that disappears into the blood vessel’s walls over the course of three years. Courtesy Abbott

An Abbott device that failed in heart disease patients is getting a new life in patients with severe vascular disease.

The device is a below-knee stent that widens clogged blood vessels, and then vanishes into the vessel’s walls over the course of three years. It also delivers a drug that prevents scar tissue from forming — a common risk factor with traditional metal stents that further narrow the vessel.

Abbott’s first dissolvable stent, for coronary artery disease, received Food and Drug Administration approval in 2016. But the company voluntarily pulled the product from the market just over a year later due to “low commercial uptake.” The device also received mixed results in clinical trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： HHS secretary Becerra pressed on Change HealthCare cyberattack

knowledge

WSS

FDA panel signals lack of confidence in Amgen cancer drug data

How many hemophilia patients actually want gene therapy?

Male and female sex labels in research insufficient, scientists say

Analysis of telehealth claims data suggest service duplication

Change Healthcare outage fallout shows need for new oversight

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

leisure time

explore

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

knowledge

Virginia high school admissions case could be legal follow

FDA rejects Alnylam's heart disease treatment over insufficient data

BioMarin wins approval for gene therapy to treat hemophilia A

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

BioMarin wins approval for gene therapy to treat hemophilia A

The future of health care in the House

How to save PrEP access — and even expand it

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

State Dept. review finds Biden bears some blame for Afghanistan failures

Readout Newsletter: CAR

focus

Was Amgen transparent enough on FDA's concern on cancer drug?

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

Why depression after traumatic brain injury is distinct

A Q&A with the global head of Boehringer Ingelheim's innovation unit

AI can decode, harness the power of the humane immune system

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

hotspot

knowledge

leisure time

knowledge